Rebekka Schairer
Tuebingen, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Characterizing the impact of MLL fusion variants and fusion partners on leukemia plasticity using a human CRISPR-engineered MLL-rearranged leukemia model.
Journal: Neoplasia (New York, N.Y.)
Published: February 25, 2026
Anti CD19 targeting CAR T cell therapy in ANCA-associated vasculitis.
Journal: Rheumatology (Oxford, England)
Published: August 19, 2025
CD19-targeting CAR T cell therapy in five patients with systemic sclerosis unsuitable for autologous stem cell transplantation.
Journal: EULAR rheumatology open
Published: April 18, 2025
PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity.
Journal: Journal for immunotherapy of cancer
Published: December 21, 2023
The RORɣ/SREBP2 pathway is a master regulator of cholesterol metabolism and serves as potential therapeutic target in t(4;11) leukemia.
Journal: Oncogene
Published: June 08, 2023
Targeting MYC in combination with epigenetic regulators induces synergistic anti-leukemic effects in MLLr leukemia and simultaneously improves immunity.
Journal: Neoplasia (New York, N.Y.)
Published: February 06, 2023
Allosteric activation of MALT1 by its ubiquitin-binding Ig3 domain.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: January 26, 2020
CARD14 Gain-of-Function Mutation Alone Is Sufficient to Drive IL-23/IL-17-Mediated Psoriasiform Skin Inflammation In Vivo.
Journal: The Journal of investigative dermatology
Published: December 18, 2017
GRK2 suppresses lymphomagenesis by inhibiting the MALT1 proto-oncoprotein.
Journal: The Journal of clinical investigation
Published: August 28, 2017
Last Updated: 09/26/2026